A 55-year-old woman with diabetes, kidney disease, and prior pancreatitis developed intractable vomiting, sepsis, and GI bleeding shortly after a tirzepatide dose increase, highlighting the risks of incretin therapy in complex patients.
Life-threatening complications after dose increaseA patient with CKD, diabetes, neuropathy, and prior pancreatitis developed sepsis and GI bleeding following tirzepatide up-titration
What the researchers found
A 55-year-old woman with chronic kidney disease, type 2 diabetes with neuropathy, peripheral vascular disease, and prior pancreatitis developed severe gastrointestinal symptoms consistent with the temporal relationship of GLP-1 receptor agonist dose titration. The case was complicated by sepsis physiology, gastrointestinal bleeding, hemodynamic instability, and metabolic derangement, requiring multidisciplinary management including endocrinology, gastroenterology, and cardiology.
Why it matters
As GLP-1 receptor agonists like tirzepatide become widely prescribed, understanding their risks in complex patients is critical. While GI side effects are well-known and usually mild, this case shows they can escalate to life-threatening complications in patients with multiple comorbidities. It underscores the need for cautious dose titration and close monitoring in high-risk populations.
How the study worked
Single patient case report describing the clinical presentation, hospital course, and management of a complex adverse drug reaction following tirzepatide up-titration in a multimorbid patient. Concurrent cannabis use was noted as a potential complicating factor.
What this study cannot tell us
As a single case report, this cannot establish incidence rates or definitively attribute all complications to tirzepatide. The patient had multiple pre-existing conditions (CKD, prior pancreatitis, neuropathy) and concurrent cannabis use, making it difficult to isolate the drug's contribution. The findings represent one extreme scenario and should not be generalized to typical GLP-1 RA users.
How to read the evidence
This is a single case report, the lowest level of clinical evidence. It describes one patient's experience and cannot establish causation, incidence, or generalizability. Its value lies in raising clinical awareness of potential severe adverse events in high-risk populations.
When this study was published
Published in 2025, this case report is highly timely given the rapid expansion of GLP-1 receptor agonist prescribing and the growing number of complex patients receiving these therapies.
The bigger picture
GLP-1 receptor agonists are among the fastest-growing drug classes worldwide, with millions of new prescriptions annually. Most safety data comes from clinical trials that excluded patients with severe comorbidities like this case. As real-world use expands to sicker, more complex patients, case reports like this are essential for understanding the full risk profile and guiding clinical decision-making in populations underrepresented in trials.
Questions still open
- Should patients with a history of pancreatitis and chronic kidney disease receive modified or slower dose titration protocols for GLP-1 receptor agonists?
- Does concurrent cannabis use — which itself can cause cyclic vomiting — compound the gastrointestinal risks of GLP-1 receptor agonists?
- Are current clinical guidelines adequately addressing the risks of incretin-based therapies in patients with multiple overlapping comorbidities?
Common questions
Can tirzepatide cause serious side effects?
Does cannabis use make GLP-1 side effects worse?
Read the original research
Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage.
Cureus, 17(11), e97851
Citation
DesRochers, Peter; Kaiser, Linus; Lee, Seoyoon; Perchetti, Garrett A; Lazarescu, Roxana. (2025). Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage.. Cureus, 17(11), e97851. https://doi.org/10.7759/cureus.97851